

Change of Director's Interest Notice

SYDNEY, Australia, 7 March 2019: Recce Pharmaceuticals Ltd (ASX: RCE) (**Company**), the Company developing a new class of synthetic antibiotics, is pleased to advise that Executive Director, James Graham, has purchased 650,000 fully paid ordinary shares in the Company on the market for a total consideration of approximately \$100,460 (an average price of \$0.1546 per share).

A Change of Director's Interest Notice is attached. The purchase of 650,000 fully paid ordinary shares is in line with Mr Graham's commitment and support to the Company's ongoing strategy and objectives.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Hamilton Bray Graham
Date of last notice	9 March 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Bulleen Pty Ltd
Date of change	Date of Trade: 1 March 2019 4 March 2019 5 March 2019 6 March 2019
No. of securities held prior to change	Direct Interest: 1. 1,868,601 ordinary shares 2. 389,712 Class B Performance Shares 3. 389,712 Class C Performance Shares 4. 389,712 Class D Performance Shares Indirect Interest: Mr. James Graham <J Graham Family A/c> 1. 1,781,250 ordinary shares 2. 356,250 Class B Performance Shares 3. 356,250 Class C Performance Shares 4. 356,250 Class D Performance Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Fully Paid Ordinary Shares
Number acquired	650,000 ordinary shares
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.1546 per Ordinary Share (Average Price) Total Consideration: approximately \$100,460
No. of securities held after change	<p>Direct Interest:</p> <ol style="list-style-type: none"> 1,868,601 ordinary shares 389,712 Class B Performance Shares 389,712 Class C Performance Shares 389,712 Class D Performance Shares <p>Indirect Interest:</p> <p>Mr. James Graham <J Graham Family A/c></p> <ol style="list-style-type: none"> 1,781,250 ordinary shares 356,250 Class B Performance Shares 356,250 Class C Performance Shares 356,250 Class D Performance Shares <p>Bulleen Pty Ltd</p> <ol style="list-style-type: none"> 650,000 ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market trade.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A

+ See chapter 19 for defined terms.

Interest after change	N/A
------------------------------	-----

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.